Mohammed Kashani-Sabet, MD
Dermatology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kashani-Sabet’s office at (415) 600-1020 to ask if they take your plan before you enroll.
California Medical Board record
Licence G75803 · Current
Licensed to practise in California · since 1993 · expires 2028-11-30 · State University of New York at Stony Brook Health Sciences Center.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$93,564
Medicare paid this office $93,564 for 500 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 361 | $33,999 | $74 |
| Destruction of precancer skin growth, 1 growth | 193 | $13,188 | $56 |
| New patient visit (45+ min) | 88 | $13,015 | $148 |
| Return visit (30+ min) | 86 | $9,655 | $104 |
| Biopsy of related skin growth, first growth | 66 | $6,949 | $98 |
See all 10 services
| Short return visit (20+ min) | 361 | $33,999 | $74 |
| Destruction of precancer skin growth, 1 growth | 193 | $13,188 | $56 |
| New patient visit (45+ min) | 88 | $13,015 | $148 |
| Return visit (30+ min) | 86 | $9,655 | $104 |
| Biopsy of related skin growth, first growth | 66 | $6,949 | $98 |
| Destruction of precancer skin growth, 2-14 growths | 164 | $5,909 | $6 |
| Destruction of precancer skin growth, 15 or more growths | 29 | $5,765 | $170 |
| New patient visit (30+ min) | 15 | $1,386 | $92 |
| Destruction of skin growth, 1-14 growths | 12 | $1,337 | $111 |
| Biopsy of related skin growth, each additional growth | 14 | $932 | $52 |
Procedures Medicare counted
| Removal of skin lesions | 564 | More than 88% of doctors who do this |
| Skin biopsy | 100 | More than 76% of doctors who do this |
Who their Medicare patients are
500 Original Medicare patients in 2024. Average age 75 · Women 42% · Also on Medicaid 3% · Health risk score 1.06. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 57% · Coronary heart disease 22% · Cancer 18% · Atrial fibrillation 17% · Diabetes 15% · Chronic kidney disease 11% · Depression 10% · COPD 7% · Heart failure 6% · Stroke 6% · Dementia 2%.
The office billed $370,385, Medicare allowed $132,229 and paid $93,564; for 1,952 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 500 | 1,952 | 75 | 1.06 | $370,385 | $93,564 |
| 2023 | 456 | 1,618 | 75 | 1.09 | $338,689 | $92,619 |
| 2022 | 471 | 1,543 | 74 | 1.09 | $302,089 | $83,651 |
| 2021 | 443 | 1,521 | 74 | 1.17 | $294,304 | $84,385 |
| 2020 | 445 | 1,451 | 75 | 1.14 | $306,207 | $74,738 |
| 2019 | 532 | 1,486 | 74 | 1.18 | $356,181 | $87,821 |
| 2018 | 490 | 1,206 | 74 | 1.16 | $291,790 | $71,851 |
| 2017 | 459 | 847 | 74 | 1.13 | $250,154 | $65,665 |
| 2016 | 417 | 818 | 74 | 1.14 | $226,328 | $58,107 |
| 2015 | 371 | 613 | 74 | 1.19 | $194,607 | $52,875 |
| 2014 | 323 | 464 | 74 | 1.14 | $153,919 | $39,898 |
| 2013 | 329 | 600 | 74 | 1.31 | $185,957 | $51,054 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Short return visit (20+ min) | 292 | $28,153 | $74 |
| Return visit (30+ min) | 119 | $14,865 | $111 |
| New patient visit (45+ min) | 93 | $14,442 | $155 |
| Destruction of precancer skin growth, 1 growth | 160 | $10,684 | $57 |
| Biopsy of related skin growth, first growth | 79 | $9,155 | $103 |
| Measurement of lymphedema extracellular fluid | 29 | $5,718 | $143 |
| Destruction of precancer skin growth, 2-14 growths | 120 | $4,165 | $7 |
| Destruction of precancer skin growth, 15 or more growths | 11 | $2,381 | $170 |
| Biopsy of related skin growth, each additional growth | 22 | $1,519 | $52 |
| New patient visit (30+ min) | 13 | $1,182 | $91 |
2022: 9 services
| Short return visit (20+ min) | 316 | $30,397 | $75 |
| Return visit (30+ min) | 128 | $14,608 | $103 |
| New patient visit (45+ min) | 77 | $11,578 | $150 |
| Destruction of precancer skin growth, 1 growth | 140 | $9,824 | $56 |
| Biopsy of related skin growth, first growth | 56 | $6,434 | $101 |
| Destruction of precancer skin growth, 2-14 growths | 112 | $4,136 | $7 |
| Destruction of precancer skin growth, 15 or more growths | 13 | $2,385 | $159 |
| Biopsy of related skin growth, each additional growth | 17 | $1,103 | $53 |
| New patient visit (30+ min) | 14 | $1,058 | $76 |
2021: 8 services
| Return visit (30+ min) | 200 | $24,940 | $107 |
| Short return visit (20+ min) | 222 | $19,514 | $74 |
| New patient visit (45+ min) | 77 | $11,881 | $154 |
| Destruction of precancer skin growth, 1 growth | 164 | $10,990 | $57 |
| Biopsy of related skin growth, first growth | 65 | $7,709 | $106 |
| Destruction of precancer skin growth, 2-14 growths | 116 | $4,108 | $7 |
| Biopsy of related skin growth, each additional growth | 17 | $1,376 | $53 |
| New patient visit (30+ min) | 11 | $965 | $88 |
2020: 8 services
| Return visit (30+ min) | 202 | $22,695 | $91 |
| New patient visit (45+ min) | 98 | $14,414 | $147 |
| Short return visit (20+ min) | 209 | $14,369 | $57 |
| Destruction of precancer skin growth, 1 growth | 147 | $9,482 | $55 |
| Biopsy of related skin growth, first growth | 48 | $5,275 | $100 |
| Destruction of precancer skin growth, 2-14 growths | 110 | $3,401 | $6 |
| Destruction of precancer skin growth, 15 or more growths | 11 | $1,642 | $149 |
| New patient visit (30+ min) | 13 | $1,130 | $87 |
2019: 9 services
| Return visit (30+ min) | 222 | $25,503 | $93 |
| Short return visit (20+ min) | 290 | $22,591 | $60 |
| New patient visit (45+ min) | 116 | $17,130 | $148 |
| Destruction of precancer skin growth, 1 growth | 134 | $8,513 | $55 |
| Biopsy of related skin growth, first growth | 67 | $6,815 | $92 |
| Destruction of precancer skin growth, 2-14 growths | 95 | $2,005 | $5 |
| Punch biopsy, first skin growth | 14 | $1,711 | $122 |
| New patient visit (30+ min) | 16 | $1,332 | $83 |
| Biopsy of related skin growth, each additional growth | 15 | $774 | $52 |
2018: 8 services
| Short return visit (20+ min) | 300 | $22,362 | $59 |
| Return visit (30+ min) | 182 | $19,423 | $87 |
| New patient visit (45+ min) | 94 | $13,029 | $139 |
| Biopsy of single growth of skin and/or tissue | 62 | $6,844 | $99 |
| Destruction of precancer skin growth, 1 growth | 91 | $6,430 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 64 | $1,410 | $5 |
| New patient visit (30+ min) | 11 | $796 | $72 |
| Biopsy of each additional growth of skin and/or tissue | 15 | $546 | $30 |
2017: 8 services
| Return visit (30+ min) | 176 | $19,311 | $91 |
| Short return visit (20+ min) | 240 | $18,602 | $61 |
| New patient visit (45+ min) | 105 | $14,951 | $142 |
| Biopsy of single growth of skin and/or tissue | 56 | $5,855 | $98 |
| Destruction of precancer skin growth, 1 growth | 63 | $4,313 | $60 |
| New patient visit (30+ min) | 13 | $1,035 | $80 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $338 | $31 |
| Destruction of precancer skin growth, 2-14 growths | 41 | $327 | $6 |
2016: 6 services
| Return visit (30+ min) | 174 | $18,657 | $87 |
| New patient visit (45+ min) | 110 | $15,649 | $142 |
| Short return visit (20+ min) | 185 | $13,192 | $59 |
| Destruction of precancer skin growth, 1 growth | 60 | $4,133 | $61 |
| Biopsy of single growth of skin and/or tissue | 39 | $3,967 | $102 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $694 | $5 |
2015: 6 services
| New patient visit (45+ min) | 123 | $17,826 | $145 |
| Return visit (30+ min) | 149 | $17,055 | $95 |
| Short return visit (20+ min) | 137 | $10,031 | $62 |
| Biopsy of single growth of skin and/or tissue | 27 | $2,816 | $104 |
| Destruction of precancer skin growth, 1 growth | 40 | $2,542 | $62 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $305 | $6 |
2014: 6 services
| New patient visit (45+ min) | 110 | $15,331 | $139 |
| Return visit (30+ min) | 109 | $10,084 | $85 |
| Short return visit (20+ min) | 135 | $9,225 | $57 |
| Destruction of precancer skin growth, 1 growth | 22 | $1,593 | $69 |
| Biopsy of single growth of skin and/or tissue | 12 | $1,154 | $96 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $153 | $10 |
2013: 7 services
| Return visit (30+ min) | 134 | $16,115 | $87 |
| New patient visit (45+ min) | 99 | $14,365 | $145 |
| Short return visit (20+ min) | 138 | $11,065 | $61 |
| Destruction of precancer skin growth, 1 growth | 32 | $2,939 | $75 |
| Biopsy of single growth of skin and/or tissue | 22 | $2,335 | $102 |
| New patient visit (30+ min) | 14 | $1,222 | $87 |
| Destruction of precancer skin growth, 2-14 growths | 21 | $190 | $7 |
Drugs they prescribed that Part D paid
$501
Pharmacies billed $501 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 25) in 2024. Too few prescriptions to compare fairly with other clinicians.
24 generic and fewer than 11 brand-name prescriptions · $501 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Triamcinolone Acetonide | 11 | $58 | $5 |
Year by year
| 2024 | 25 | 22 | 0% (0) | None | $501 |
| 2023 | 41 | 28 | None | 0% | $737 |
| 2022 | 26 | 18 | 0% (0) | 0% | $576 |
| 2021 | 40 | 16 | 0% (0) | 0% | $3,323 |
| 2020 | 33 | 18 | 0% (0) | None | $3,055 |
| 2019 | 38 | 16 | 0% (0) | 0% | $3,698 |
| 2018 | 28 | 12 | 0% (0) | None | $4,367 |
| 2017 | 24 | 14 | 0% (0) | None | $3,385 |
| 2016 | 41 | 16 | 0% (0) | None | $10,869 |
| 2015 | 12 | None | 0% (0) | None | $2,154 |
| 2014 | 26 | None | 0% (0) | None | $1,713 |
| 2013 | 50 | 17 | None | None | $33,989 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Triamcinolone Acetonide | 19 | $139 | $7 |
2022: 1 drug
| Triamcinolone Acetonide | 13 | $64 | $5 |
2019: 1 drug
| Clobetasol Propionate | 12 | $1,798 | $150 |
2018: 1 drug
| Clobetasol Propionate | 14 | $2,795 | $200 |
2016: 1 drug
| Clobetasol Propionate | 29 | $9,743 | $336 |
2013: 1 drug
| Clobetasol Propionate | 11 | $336 | $31 |
Money from drug and device companies
$70 in 2025
| 2025 | 2 | 2 | None | $70 |
| 2024 | 6 | 6 | None | $246 |
| 2023 | 1 | 1 | None | $37 |
| 2021 | 2 | 2 | $1,953 | $2,060 |
| 2020 | 2 | 2 | None | $40 |
| 2019 | 3 | 9 | None | $267 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Libtayo | $39 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $31 | 1 payment
|
See all 2 published payments
| Regeneron Healthcare Solutions | Meals · 2025-07-07 | Libtayo | $39 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-24 | Opdivo | $31 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $246
| Envista Holdings | Tf | $96 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $32 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $30 | 1 payment
|
| Kyowa Kirin | Poteligeo | $30 | 1 payment
|
| Hologic Sales and Service | Trunode | $29 | 1 payment
|
| Array Biopharma | Braftovi | $28 | 1 payment
|
2023: $37
| Regeneron Healthcare Solutions | Libtayo | $37 | 1 payment
|
2021: $2,060
| E.R. Squibb & Sons L.L.C. | Opdivo | $1,953 | 1 payment
|
| Seagen | Tukysa | $107 | 1 payment
|
2020: $40
| E.R. Squibb & Sons L.L.C. | None | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $19 | 1 payment
|
2019: $267
| Merck Sharp & Dohme | Keytruda | $158 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | None | $95 | 5 payments
|
| Ge Healthcare | None | $14 | 1 payment
|
Professional record
- NPI
- 1629026174
- Licence
- CA G75803California G75803: Current · expires 2028-11-30
- Trained
- State University of New York at Stony Brook, School of Medicine, 1991
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G758030
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 2340 Clay Street, 2nd Floor, San Francisco, CA, 94115
- NPI first listed
- 2006-05-05
- NPI last updated
- 2010-08-10
This is when the NPI record was last certified, not a medical board exam.